Alderuccio JP et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial. Lancet Haematol 2025;12(1):e23-34. Abstract

Alderuccio JP et al. Loncastuximab tesirine with rituximab induces robust and durable complete metabolic responses in high-risk relapsed/refractory follicular lymphoma. ASH 2024;Abstract 337.

Batlevi CL et al. Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Phase 1b results of symphony-1. Blood 2022;140(Supplement 1):2296-8. Abstract

Chavez JC et al. Golcadomide (GOLCA) ± rituximab (RTX) demonstrates durable efficacy and is well tolerated in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): Updated results from the phase 1/2 CC-99282-NHL-001 study. ASH 2024;Abstract 3018.

Jurczak W et al. Nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma: Results from the phase 2 Bellwave-003 study. ASH 2024;Abstract 1634.

Morschhauser F et al.Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21(11):1433-42. Abstract

Salles G et al. Efficacy of subcutaneous epcoritamab vs tisa-cel in R/R LBCL CAR T-naive and CAR T-eligible patients: An indirect comparison. ASH 2023;Abstract 1733.

Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA1.

Trotman J et al. Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the Rosewood study. EHA 2023;Abstract P1080.

Zinzani PL et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 2023;41(33):5107-17. Abstract